{
  "paper_id": "PMC8529524",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529524/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.  Cumulative Risks in All Organ Transplant Recipients.",
      "caption": "Cumulative risk of first skin cancer treatment in Optum electronic health record (EHR) data set (A) and in MarketScan claims (B). Cumulative risk of subsequent skin cancer treatments in Optum EHR data set (C) and in MarketScan claims (D). Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/c3e4ac17a34f/jamadermatol-e214148-g001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/c3e4ac17a34f/jamadermatol-e214148-g001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/c3e4ac17a34f/jamadermatol-e214148-g001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/c3e4ac17a34f/jamadermatol-e214148-g001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "doi210056f1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/c3e4ac17a34f/jamadermatol-e214148-g001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8529524/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/c3e4ac17a34f/jamadermatol-e214148-g001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.  Cumulative Risk of Having at Least 10 Skin Cancers Treated in Patients Who Had Already Had 1 Skin Cancer Treatment.",
      "caption": "Cumulative risk among Optum electronic health record (EHR) data set (A) and MarketScan claims (B).",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/25359bf17cc5/jamadermatol-e214148-g002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/25359bf17cc5/jamadermatol-e214148-g002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/25359bf17cc5/jamadermatol-e214148-g002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/25359bf17cc5/jamadermatol-e214148-g002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "doi210056f2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/25359bf17cc5/jamadermatol-e214148-g002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8529524/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ceec/8529524/25359bf17cc5/jamadermatol-e214148-g002.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Groups indicate the time interval at risk (first skin cancer treatment encounter to second, second to third, third to fourth, and fourth to fifth).Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cumulative risk curves (Figure 1A and B) demonstrated a 2.7% risk of first skin cancer treatment at 2 years after a first transplant code in Optum, and 12.4% in MarketScan.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For OTRs who had already had 1 skin cancer treatment (Figure 1C and D), we observed an approximately 45% risk in Optum and 57% risk in MarketScan at 2 years after a first skin cancer treatment encounter, and an approximately 62% risk in Optum and 89% risk in MarketScan at 2 years after a second and third skin cancer treatment encounter.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The risk of having 10 or more skin cancers treated was approximately 3% in Optum and 7% in MarketScan at 2 years after the first skin cancer treatment encounter (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 39,
    "images_downloaded": 2,
    "tables_filtered": 55
  }
}